Division of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida 33136, USA.
Cancer Invest. 2012 Dec;30(10):727-31. doi: 10.3109/07357907.2012.732163. Epub 2012 Oct 12.
In this multicenter phase Ib study, drozitumab was given in combination with the mFOLFOX6 regimen and bevacizumab in patients with previously untreated, locally advanced recurrent or metastatic colorectal cancer on day 1 of every 14-day cycle. Nine patients were treated at 2 different cohort dose levels of drozitumab. No dose-limiting toxicities occurred at either dose level and the maximum tolerated dose was not reached. Two patients had a partial response of 4.93 and 4.96 months duration. Cohort 2 dose level is the recommended starting dose level for future trials.
在这项多中心 Ib 期研究中，在每 14 天周期的第 1 天，给予 drozitumab 联合 mFOLFOX6 方案和 bevacizumab 治疗未经治疗的局部晚期复发性或转移性结直肠癌患者。9 名患者在 drozitumab 的 2 个不同队列剂量水平下接受治疗。两个剂量水平均未发生剂量限制性毒性，未达到最大耐受剂量。两名患者的部分缓解持续时间分别为 4.93 个月和 4.96 个月。队列 2 剂量水平是未来试验的推荐起始剂量水平。
